雲頂新耀(01952.HK)曾急跌19%創上市新低 終止腫瘤藥物授權開發
雲頂新耀-B(01952.HK)終止腫瘤藥物授權開發,該股今早曾急跌19%低見13.62元創上市新低,半日收14.2元,急跌16%,一向薄弱成交急增至370萬股,創逾兩個月高,涉資5,280萬元。
雲頂新耀公布,全資附屬Everest Medicines II及Everest SG昨天與吉利德(GILD.US)全資附屬Immunomedics訂立終止及過渡服務協議,以終止對方向集團授出腫瘤藥物Sacituzumab govitecan獨家許可開發權,而集團將向Immunomedics轉讓其與授權產品相關全部知識產權、監管材料和其他資產,以及提供過渡服務,使Immunomedics或其聯屬公司能夠在有關地區開發及商業化授權產品,而集團則可獲得最高代價約4.55億美元,料該交易將產生最多收益3.14億美元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.